Global Insulin Glargine Market 2016 - Novo Nordisk, Eli Lilly, Tonghua Dongbao, Gan & Lee

Global Insulin glargine market under the names Lantus among others, is a long-acting basal insulin analogue, given once daily to help control the blood sugar level of those with diabetes. It consists of microcrystals that slowly release insulin, giving a long duration of action of 18 to 26 hours, with a "peakless" profile (according to the insulin glargine package insert). Pharmacokinetically, it resembles basal insulin secretion of non-diabetic pancreatic beta cells.

Sometimes, in type 2 diabetes and in combination with a short acting sulfonylurea (drugs which stimulate the pancreas to make more insulin), it can offer moderate control of serum glucose levels. In the absence of endogenous insulin—type 1 diabetes, depleted type 2 (in some cases) or latent autoimmune diabetes of adults in late stage—insulin glargine needs the support of fast acting insulin taken with food to reduce the effect of prandially derived glucose.

Browse full report with TOC @ https://goo.gl/WuJ84S

This report provides detailed analysis of worldwide markets for Insulin Glargine from 2011-2016, and provides extensive market forecasts (2016-2021) by region/country and subsectors. It covers the key technological and market trends in the Insulin Glargine market and further lays out an analysis of the factors influencing the supply/demand for Hydroxypropyl Methylcellulose (HPMC), and the opportunities/challenges faced by industry participants. It also acts as an essential tool to companies active across the value chain and to the new entrants by enabling them to capitalize the opportunities and develop business strategies.

Global Insulin Glargine Market Outlook 2016-2021, has been prepared based on the synthesis, analysis, and interpretation of information about the global Insulin Glargine market collected from specialized sources. The report covers key technological developments in the recent times and profiles leading players in the market and analyzes their key strategies.

The major players in the global Insulin Glargine market are,
Sanofi (France)
Novo Nordisk (Demark)
Eli Lilly (USA)
Tonghua Dongbao (China)
Gan & Lee (China)

For sample request click on https://goo.gl/YjDI4Z

The report provides separate comprehensive analytics for the North America, Europe, Asia-Pacific, Middle East and Africa and Rest of World. In this sector, global competitive landscape and supply/demand pattern of Insulin Glargine industry has been provided.

About Market Research Store:

Market Research Store is a single destination for all the industry, company and country reports. We feature large repository of latest industry reports, leading and niche company profiles, and market statistics released by reputed private publishers and public organizations. Market Research Store is the comprehensive collection of market intelligence products and services available on air. We have market research reports from number of leading publishers and update our collection daily to provide our clients with the instant online access to our database. With access to this database, our clients will be able to benefit from expert insights on global industries, products, and market trends.

3422 SW 15 Street,Suit #8138,
Deerfield Beach,Florida 33442, USA

This release was published on openPR.